Boucher Kelley (CIK 2070437) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-14). Recent activity: Sell APLS (22,087 shares), Buy APLS (15,073 shares), Sell APLS (15,073 shares), Buy APLS (30,146 shares), Sell APLS (30,146 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 22,087 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 15,073 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 15,073 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 30,146 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 30,146 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 127,804 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 45,095 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 30,476 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Sell | 30,146 | $0 |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 30,146 | $0 |
| 2025-09-03 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 30,476 | $0 |
| 2025-06-11 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 45,095 | $0 |
| 2025-05-29 | Apellis Pharmaceuticals, Inc. (APLS) | Chief People Officer | Buy | 22,087 | $0 |
Source: SEC Form 4 filings · as of 2026-05-14